首页> 外文OA文献 >NP-012 Cost effectiveness analysis and indirect comparison can support the price’ definition of a drug? The case of encorafenib and binimetinib in metastatic melanoma, the pharmacist’s point of view

【2h】

NP-012 Cost effectiveness analysis and indirect comparison can support the price’ definition of a drug? The case of encorafenib and binimetinib in metastatic melanoma, the pharmacist’s point of view

机译：NP-012成本效益分析和间接比较可以支持价格的定义吗？转移性黑素瘤中的encorafenib和binimetinib，药剂师的观点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A Marinozzi; AMP Mangano; E Antonicelli; A Caprodossi; R Connestari; M Lalli; E Maradonna; R Berardi; L Patregnani;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第期

机译：哥伦布的可耐受性和整体存活的更新：随机阶段3核酰胺in患者的随机阶段3试验的载体分析vemimetinib患者中的Binureafenib或Encorafenib患者
2. Encorafenib + binimetinib: a profile of their combined use in treating BRAF-mutated unresectable or metastatic melanoma [J] . Katherine A. Lyseng-Williamson Drugs & therapy perspectives: for rational drug selection and use . 2019,第4期

机译：EncorafeNib + Binimetinib：它们在治疗BRAF突变的不可切除或转移性黑色素瘤中使用的剖面
3. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations [J] . Trojaniello Claudia, Festino Lucia, Vanella Vito, Expert review of clinical pharmacology . 2019,第1a6期

机译：Encorafenib与Binimetinib结合使用BRAF突变的不可切除或转移性黑素瘤
4. Telemedicine-islands project: cost-effectiveness and cost-comparison analysis [C] . Bracale, M., Cesarelli, Engineering in Medicine and Biology Society, 2000. Proceedings of the 22nd Annual International Conference of the IEEE . 2000

机译：远程医疗-岛屿项目：成本效益和成本比较分析
5. Does Taking a More Holistic View of Personality Improve its Predictive Utility? A Comparison Multiple Regression, Fuzzy Cluster Analysis, and Indirect Mixture Modeling for Predicting Leadership Effectiveness. [D] . Yost, Allison Brown. 2014

机译：从整体角度看待人格会提高其预测效用吗？比较多元回归，模糊聚类分析和间接混合建模以预测领导力有效性。
6. Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [O] . Rachel Houten, Janette Greenhalgh, James Mahon, 2021

机译：与Binimetinib的Encorafenib用于治疗BRAF V600突变阳性不可切除或转移黑素瘤的患者：证据审查集团的观点这是一个很好的单一技术评估
7. Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [O] . Rachel Houten, Janette Greenhalgh, James Mahon, 2020

机译：与Binimetinib的Encorafenib用于治疗BRAF V600突变阳性不可切除或转移黑素瘤的患者：证据审查集团的观点，这是一个很好的单一技术评估
8. An Analysis of Forward Pricing Rates and Their Effectiveness in Indirect Cost Management. [R] . Jones, T. G., Volpe, R. L. 1978

机译：间接成本管理中的远期定价率及其有效性分析。

NP-012 Cost effectiveness analysis and indirect comparison can support the price’ definition of a drug? The case of encorafenib and binimetinib in metastatic melanoma, the pharmacist’s point of view

著录项

引文网络

相似文献

相关主题

期刊订阅